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Abstract
We consider a class of normal transformation models for clustered failure
time data. The failure time outcomes are assumed to marginally follow a proportional hazards model, while the normally transformed variates allow a shared
frailty. As a result, the model permits population-level interpretation of covariates in the proportional hazards model, but also directly models the correlation
of the transformed failure times. The method allows for varying cluster sizes,
and we are able to predict shared frailties for the transformed failure times.
Predictions of the frailties allow us to evaluate the role of underlying cluster
effects on subjects’ survival. We propose a profile estimation procedure and
derive asymptotic properties under this estimation scheme. Simulation studies
verify finite sample utility. We apply the method to a Children’s Oncology
Group multi-center study of acute lymphoblastic leukemia. The analysis estimates marginal treatment effects and examines potential clustering within
treatment institution.

Keywords: Semiparametric normal transformation, frailty model, marginal model,
correlated survival data, proportional hazards model
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Introduction

Two major branches of models for correlated survival data are frailty models (Oakes
1989; Murphy 1994, 1995; Parner 1998) and marginal models (Wei, Lin, and Weissfeld
1989; Prentice and Cai 1992; Cai and Prentice 1995). The parameters from these two
approaches have different interpretations and hence are appropriate in different contexts. For example, frailty models are used when within cluster inferences are desired.
Frailty models account for dependence by including a multiplicative term (called a
frailty or a random-effect) in the model for the hazard. The multiplicative nature of
the frailty term implies that parameters have interpretations conditional on the value
of the frailty. In contrast, marginal models directly model the marginal failure time
and within cluster correlations are treated as a nuisance. With marginal models, the
correlated nature of the data is often accounted for by using a sandwich-type variance.
The parameters of marginal models have population-average interpretations.
In some correlated survival data settings, practitioners have two primary interests:
assessing the effect of treatment or exposure on the marginal survival distribution
and determining the dependence between subjects. For example, in many multicenter clinical trials data are clustered within treatment center. Clinical researchers
are interested in the unconditional treatment effect observed in the study, which can
be found via marginal modeling. Although institutions participating in clinical trials
follow trial-specific protocols, differences can still exist between outcomes (Fleiss 1986;
Gray 1994; Jones, Teather, Wang, and Lewis 1998; Senn 1998; Anello, O’Neill, and
Dubey 2005; Vierron and Giraudeau 2007; Logan, Nelson, and Klein 2008; Zheng and
Zelen 2008). The correlation between patients treated at the same institution is an
important component of a multi-center clinical trial analysis.
Our motivating data come from a large multi-center clinical trial for children with
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“higher risk” acute lymphoblastic leukemia. The goal of the study was to evaluate
the effect of different treatments on survival. We are interested in evaluating whether
there existed substantial variation between institutions while concurrently assessing
the efficacy of the new treatments.
To this end we propose a marginalized frailty model, which models the marginal
failure times with the proportional hazards model (Cox 1972) and models the correlation by assuming that normally transformed survival times follow a shared frailty
model. This project extends previous work on normal transformation models (e.g.
Li and Lin (2006); Li, Prentice, and Lin (2008)) in four major ways. First, Li et al.
(2008) use a likelihood method that does not allow for covariates and is restricted to
bivariate data. Our model allows for covariates and varying cluster sizes. Second, Li
and Lin (2006) assume a specific spatial correlation structure on the entire dataset.
Our method explicitly allows for correlated survival times within independent clusters. Third, we establish a likelihood framework for inference for general regression
models for the normally-transformed survival times. Finally, we provide a method
for predicting cluster-level effects, providing information that can be used to evaluate
individual clusters.
The rest of the paper is structured as follows: in Section 2 we define notation and
describe the model; Section 3 provides methods to estimate the marginal survival
parameters, the correlation parameter, and the frailties; we provide a summary of
asymptotic results in Section 4; we outline a model-checking procedure in Section 5;
simulations are presented in Section 6; Section 7 contains an analysis of Children’s
Oncology Group study 1961; and we finish with a brief discussion in Section 8. Regularity conditions and detailed proofs of theorems are contained in the Appendix.
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Model Specification

Let Tij and Cij denote potentially unobserved failure and censoring times for subject
j in cluster i, where j = 1, . . . , ni and i = 1, . . . , m. The observed data are Xij =
min(Tij , Cij ) and ∆ij = I(Tij ≤ Cij ). Let Zij (t) denote an external time-dependent
covariate vector (Kalbfleisch and Prentice 2003, page 197) of length p and write its
covariate path up to time t as Z̄ij (t) = {Zij (s) | 0 ≤ s ≤ t}. Assume that Tij ,
conditional on the covariate process Z̄ij (Tij ), is independent of Cij . Also, assume
that, conditional on each individual’s covariate path, the hazard of Tij follows a
proportional hazards model where λ{t | Z̄ij (t)} is equal to
lim h−1 P {t ≤ Tij < t + h | Tij ≥ t, Z̄ij (t)} = λ0 (t) exp{β 0 Zij (t)}.

h→0

(1)

Here β is a vector of regression coefficients and λ0 (t) is an unspecified baseline hazard
function with cumulative hazard function Λ. Equation (1) is a marginal model for each
Tij , hence β has a population-level interpretation not a cluster-specific interpretation.
To model the clustering of the Tij , consider the semiparametric normal transformation:

T̃ij = Φ−1 [1 − S{Tij | Z̄ij (Tij )}],

(2)

where Φ is the standard normal distribution function, Φ−1 is the inverse of the standard normal distribution function, and S is the survival function associated with
Equation (1). By the probability integral transform, 1 − S{Tij | Z̄ij (Tij )} has a
Uniform(0, 1) distribution. It necessarily follows that T̃ij ∼ Normal(0, 1). The transformation takes Tij with support on (0, ∞) and transforms it to a standard normal
random variable.
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Denote the correlation of (T̃i1 , . . . , T̃ini ) with Σi . We propose to model the transformed survival times from Equation (2) with a shared frailty model:

T̃ij =

√

σbi + ij ,

(3)

where the cluster level frailty bi has a standard normal distribution and the error
terms, ij , are independent and identically distributed N (0, 1 − σ) random variables
that are also independent of bi . We call the class of models described by Equations
(1), (2), and (3) marginalized frailty models. The β parameters in Equation (1) have
marginal interpretation, while σ and bi from Equation (3) characterize the cluster
effect. The term σ can have the interpretation as the proportion of explained variance
shared by members of the same cluster. In the context of a multi-center clinical trial,
the cluster level frailties characterize the center effect. Using this model, Σi will
have an exchangeable structure with diagonal elements equal to 1 and off-diagonal
elements equal to σ.

3.
3.1.

Inference
Likelihood Function

√
The survival function for Tij | bi can be written P (Tij > t | bi ) = 1 − Φ1−σ (t̃ − σbi ),
√
with density function fij (t) = φ1−σ (t̃ − σbi )f {t | Z̄ij (t)}/φ1−σ (t̃), where t̃ = Φ−1 [1 −
S{t | Z̄ij (t)}], Φ1−σ is the distribution function for ij , φ1−σ is the density of ij , and
f {t | Z̄ij (t)} is the density associated with Equation (1). Let Φ̃1−σ (t) = 1 − Φ1−σ (t)
and X̃ij = Φ−1 [1 − S{Xij | Z̄ij (Xij )}]. Here X̃ij is a potentially censored version
of T̃ij (Equation (2)). The semiparametric normal transformation is monotone and
thus preserves censoring patterns. The likelihood based on the observed data can be
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written

L(σ, β, Λ) =

ni
m Z Y
Y
i=1

Z
×(exp[

Xij

Φ̃1−σ (X̃ij −

√

σbi )1−∆ij [λ0 (Xij ) exp{β 0 Zij (Xij )}]∆ij

j=1

exp{β 0 Zij (s)} dΛ(s)]φ1−σ (X̃ij −

√

σbi )/φ1−σ (X̃ij ))∆ij dΦ(bi )

0
ni
m Z Y
Y
=
[f {Xij | Z̄ij (Xij )}/φ1−σ (X̃ij )]∆ij
i=1

j=1

×φ1−σ (X̃ij −

√
√
σbi )∆ij Φ̃1−σ (X̃ij − σbi )1−∆ij dΦ(bi ).

Conveniently, L(σ, β, Λ) has a closed form expression proportional to a product
P i
∆ij ,
of multivariate normal terms. To simplify the presentation, define ∆i = nj=1
i
order the observations such that ∆i1 = . . . = ∆i∆i = 1, and let X̃∆
i = (X̃i1 , . . . , X̃i∆i )

and X̃ni i −∆i = (X̃i∆i+1 , . . . , X̃ini ).
Then L(σ, β, Λ) can be written
m
Y

∆i
ni −∆i
i
(X̃ni i −∆i
φ∆
u (X̃i )Φ̃c

|

i
X̃∆
i )

ni
Y
[f {Xij | Z̄ij (Xij )}/φ1−σ (X̃ij )]∆ij ,
j=1

i=1

i
where φ∆
u is the multivariate normal density corresponding to its argument and

Φ̃nc i −∆i is the multivariate normal survival function corresponding to its argument.
The distribution of each of the arguments will be outlined below. Let Σi be the covariance matrix for the transformed failure times. Write Σi as a partitioned matrix:

Σi =

Σi11 Σi12


,

Σi21 Σi22
i
where Σi11 has dimension ∆i × ∆i . The vector X̃∆
follows a multivariate normal
i

distribution with mean 0 and covariance matrix Σi11 . For the second term of the
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i
likelihood, X̃ni i −∆i | X̃∆
is a censored observation from a normal distribution with
i

i∆0i

and covariance matrix Σi22 − Σi21 Σ−1
i11 Σi12 .

mean Σi21 Σ−1
i11 X̃i

To shed some light on the likelihood, L(σ, β, Λ), we consider an example likelihood
contribution from a cluster of size two where one subject is observed to be censored
at time CA1 and one subject is observed to fail at time TA2 . The covariate process for
each subject is denoted Z̄A1 (CA1 ) and Z̄A2 (TA2 ). The normally transformed observed
failure times are X̃A1 = Φ−1 [1 − S{CA1 | Z̄A1 (CA1 )}] and X̃A2 = Φ−1 [1 − S{TA2 |
Z̄A2 (TA2 )}]. In this case

Σ=

1 σ


.

σ 1
The first term of L(σ, β, Λ) can be written

2
φ1u (X̃A2 ) = (2π)−1/2 exp(−X̃A2
/2)

(4)

while the second term can be written

Φ1c (X̃A1 )

Z

∞

=

√
{2π(1 − σ 2 )}−1/2 exp{−(x − σ X̃A2 )2 /2 1 − σ 2 } dx.

(5)

X̃A1

Equation (4) is the density of a standard normal random variable, while Equation
(5) corresponds to, conditional on X̃A2 , the probability that a Normal(σ X̃A2 , 1 − σ 2 )
random variable is greater than X̃A1 .
3.2.

Profile Likelihood Estimation

We propose a profile method to estimate (σ, β, Λ):
Step 1: Estimate β and Λ assuming working independence. Denote these estimates β̂
and Λ̂.
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Step 2: Estimate σ as the maximum of L(σ, β̂, Λ̂). Write this maximum as σ̂.
Formulas for the standard errors of β̂ and Λ̂ can be found using a sandwich
formula (Spiekerman and Lin 1998). The standard error of σ̂ needs to account for
the variability from β̂ and Λ̂. This can be accomplished using a jackknife resampling
scheme. To maintain the correlated structure of the failure times, the clusters should
be the unit of removal for the jackknife calculations (Cai et al. 1997; Cai and Shen
2000).
This estimation procedure is computationally straightforward. Marginal estimates
of the survival function assuming working independence are available in all standard
computing programs. The likelihood for σ, L(σ, β̂, Λ̂), is proportional to a product of
multivariate normal terms. The multivariate normal terms can be evaluated quickly
using existing software (e.g. R package mvtnorm).
3.3.

Predictions of Shared Frailties

Our marginalized frailty model allows us to estimate the shared frailties, which is
often of interest. In the context of institutional clustering, the bi can provide information on the results of individual institutions participating in a clinical trial.
Estimates of the bi and their standard errors can be found using Laplace approximations to the bi ’s first two moments. Denote the observed data for the ith cluster,
(Xi1 , . . . , Xini , ∆i1 , . . . , ∆ini , Z̄i1 (Xi1 ), . . . , Z̄ini (Xini )), with Ψi . The conditional density of bi given the observed data Ψi , denoted g(bi | Ψi ; σ, β, Λ), can be written
−1/2
L−1
i (2π)

exp(−b2i /2)

ni
Y
[f {Xij | Z̄ij (Xij )}/φ1−σ (X̃ij )]∆ij
j=1

√
√
×φ1−σ (X̃ij − σbi )∆ij Φ̃1−σ (X̃ij − σbi )1−∆ij
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where Li is the likelihood for Ψi | σ, β, Λ. Define ki such that g(bi | Ψi ; σ, β, Λ) =
L−1
i exp{ki (bi | Ψi ; σ, β, Λ)}. Using the Laplace approximations to the first two moments of g(bi | Ψi ; σ, β, Λ) (Booth and Hobert 1998), the predicted estimate and
variance of bi are taken to be:

b̂i = E(bi | Ψi ) ≈ arg max ki (bi | Ψi ; σ̂, β̂, Λ̂)

(6)

V (bi | Ψi ) ≈ −k̈i (b̂i | Ψi ; σ̂, β̂, Λ̂)−1 ,

(7)

bi

where double superscript dots denote second derivatives.
The prediction of the shared frailties is straightforward and computationally fast,
particularly in contrast to standard gamma frailty algorithms, which can involve
analytically complicated integrals. The expression for ki (bi | σ̂, β̂, Λ̂, Ψi ) involves ni
normal terms and can be maximized using any standard optimization routine. The
estimate of the variance of bi has a closed form expression and can be found by
plugging in relevant estimated quantities.

4.

Theoretical Results

The following theorems establish the theoretical properties of (σ̂, β̂, Λ̂) where their
true values are denoted with (σ0 , β 0 , Λ0 ).
Theorem 1. Under Conditions C.1 – C.6 in the Appendix, (σ̂, β̂, Λ̂) converges in
probability to (σ0 , β 0 , Λ0 ) as m → ∞.
√
Theorem 2. Under Conditions C.1 – C.7 in the Appendix, as m → ∞, m(σ̂ − σ0 )
√
√
and m(β̂ − β 0 ) converge to zero-mean normal distributions and m{Λ̂(t) − Λ0 (t)}
converges to a zero-mean Gaussian process.
Detailed proofs can be found in the Appendix. The proofs of both theorems for σ̂
involve accounting for the proposed profile estimation method. These theorems verify
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that σ̂ is consistent and asymptotically normal when plug-in estimates of β and Λ
are used in the likelihood function.
To prove that σ̂ is consistent we first have to verify that the log-likelihood function
is Hadamard differentiable with respect to Λ0 (van der Vaart 1998). The next step
is to show that the first order terms of a Taylor series expansion of the log-likelihood
around β 0 and Λ0 are bounded. The final key step is to prove that the log-likelihood
function with plug-in estimates for β and Λ converges uniformly to the expected value
of the log-likelihood function evaluated at the true values for β and Λ.
The proof of normality for σ̂ accounts for the profile estimation scheme by inflating
the variance term to account for using β̂ and Λ̂. The key step of the proof is to show
that the score equation can asymptotically be written as the sum of independent
and identically distributed terms, facilitating the use of the central limit theorem.
To make this argument we need to prove that the score equation for σ is Hadamard
differentiable with respect to Λ0 and that the first order terms of a Taylor series
expansion of the score function around β 0 and Λ0 are bounded.
The analytical formula for the variance of σ̂ is so complicated that it is of little
computational utility. To evaluate the finite sample variability of σ̂ we propose to
use a jackknife resampling scheme. We evaluate the performance of the jackknife by
simulation studies, which are presented in Section 6. The jackknife estimates of the
standard error match well with Monte Carlo estimates of the standard error with
moderate numbers of clusters.

5.

Model-checking

In practice, it is often of interest to verify that any assumptions made during modeling
are plausible. We propose a two-step model-checking procedure. As the marginal
survival function is modeled using proportional hazards regression, a natural first
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model-checking step is to verify that the associated regression assumptions are not
violated. In our application, we use the method of Grambsch and Therneau (1994),
though there have been many other methods proposed, such as Lin, Wei, and Ying
(1993). Next, provided that the proportional hazards model fit is adequate, the
assumption that the transformed failure times follow a shared frailty model (Equation
(3)) can be checked.
Recall that S{· | Z̄ij (Tij )} is the survival function associated with the marginal
survival time Tij . If S is estimated well, with estimate denoted Ŝ, the probability
integral transform indicates that it should be the case that Φ−1 {1 − Ŝ(Tij | Z̄ij (Tij ))}
approximately follows a standard normal distribution. In verifying the assumptions
of Equation (3), we need to check that the estimates of the frailties are normally disq
tributed. To this end, let zi = b̂i / V (b̂i ), where b̂i and V (b̂i ) are defined in Equations
(6) and (7). A simple graphical check of the assumption that the bi are normally distributed is a quantile-quantile plot (Q-Q plot) of the cumulative distribution function
of the zi .

6.

Simulation Results

We conducted a number of simulations to evaluate the efficacy of the proposed
method. The presented simulations have marginal survival times from a proportional hazards model with a constant baseline hazard function equal to 1 and with
two covariates: one Bernoulli(0.5) covariate with parameter equal to log(0.5) (denoted β1 ) and one Uniform(0, 1) covariate with parameter equal to 0.75 (denoted
β2 ). Censoring times were taken from the Exponential(mean=3) distribution and
produced about a 25% censoring rate. Clustering was induced through generating
survival times using Equation (3). The precision of σ̂ is determined by the number of
clusters, while the precision of the predicted frailties is determined by the sample size
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in individual clusters. Each simulation is based on 500 replications. We summarize
results for simulated datasets with 30, 60, and 90 clusters. The individual clusters
sizes either varied between 2 and 10 with a median size of 3, or varied between 10
and 50 with median cluster size 17.
Simulation results are presented in Table 1. Even with small cluster sizes the
estimates of σ are relatively unbiased and the jackknife standard errors match well
with the Monte Carlo standard errors. For example, in a simulation of 30 clusters
with median cluster size 3 the average estimate for σ is 0.531 (truth = 0.5), while in
a simulation of 90 clusters with median cluster size 3 the average estimate for σ is
0.512.
The jackknife estimates of the standard errors for β1 and β2 are closer to the
Monte Carlo standard errors than the sandwich-based standard errors for almost all
the simulations. For example, in a simulation of 30 clusters with median size 3, the
jackknife standard error of β2 is 0.400, which is very close to the Monte Carlo standard
error of 0.403, while the sandwich-based standard error is 0.366. In a simulation of 60
clusters with median size 17, the Monte Carlo and jackknife standard error estimates
of β1 are 0.079 and the sandwich-based standard error estimate is 0.077.
With respect to the frailty estimates, the median relative bias decreases and the
likelihood-based standard error and the Monte Carlo standard error approach one as
the individual cluster sizes increase. For example, in a simulation of 90 clusters with
median cluster size 3 the median relative bias was -0.032 and in a simulation of 30
clusters with median size 3 the likelihood-based standard errors have an average value
of 0.911.
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Data Application: Children’s Oncology Group Study 1961

We apply our method to a Children’s Oncology Group study (protocol number 1961)
(Seibel et al. 2008). The study population included 460 children with enlarged livers.
The goal of this study was to determine whether increasing the intensity of therapy
by increasing duration or strength for “higher risk” acute lymphoblastic leukemia
patients would improve survival. To evaluate the relative benefit or harm for each
type of intensification, a 2x2 factorial design with block randomization of patients
was used. The distribution of subjects with enlarged livers among the four arms is
presented in Table 2. We focus on the overall survival endpoint.
We present regression results for an analysis with a marginal survival model containing covariates for strength and duration of treatment in Table 3. We note that
there was no evidence of a duration by strength interaction in the initial analysis of
the entire dataset (Seibel et al. 2008) or in this enlarged liver subset. The p-value
for increased strength of treatment is marginally significant (p-value = 0.056, using
sandwich standard error) and indicates that increased strength of treatment may be
associated with improved survival. The p-value for increased duration of treatment is
marginally significant (p-value = 0.063, using sandwich standard error) and indicates
that duration strength of treatment may be associated with worsened survival. For
both survival parameters, the sandwich-based standard error and jackknife standard
error estimates that account for clustering within institutions provide smaller standard error estimates than the naı̈ve method assuming independence. The estimate
for σ is 0.171 with a standard error of 0.152.
We also include results for a larger survival model that includes gender and potential prognostic factors age and platelet count at diagnosis. Regression results are
summarized in Table 3. The p-values for increased strength (p-value = 0.067, using
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sandwich standard error) and increased duration (p-value = 0.071, using sandwich
standard error) are slightly larger in this larger model, but the direction of the effect
remains the same. None of the p-values for gender, age, or platelets at diagnosis is
significant. The estimate of σ increases slightly to 0.175 with standard error of 0.144.
We predicted the frailties for each of the institutions in the sample using the
treatment only survival model. A summary of the distributions of the predictions can
be found in Figure 1. The mean of the frailties is close to zero (0.024). A Q-Q plot
with standardized predicted frailties compared to theoretical normal quantiles and
the smoothed density of the predicted frailties indicate that the normal assumption
in approximately satisfied.
We also provide a scatter plot of the predicted frailties and the number of patients
enrolled at each institution in Figure 2. In general, it appears that the predicted
frailties are larger with larger sample sizes. It may be the case that institutions with
more patients have more practice with a trial protocol, which could lead to better
performance.
The two most extreme standardized frailties in the Q-Q plot are marked at the
bottom of Figure 1. The same institutions are marked in Figure 2. These institutions
have more negative predicted frailty values than might be expected given the trends
in the rest of the data. This might be due to the worse than normal outcomes in
these two institutions. Specifically, among the 460 patients in this subset, 14.8% have
died. However, in the institution with 22 patients, the failure rate was 27.3% and, in
the institution with 10 patients, the failure rate was 60%.

8.

Discussion

There is a need for flexible survival regression models that allow for marginal interpretations of treatment or exposure, while concurrently evaluating potential clustering.
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The method proposed here establishes a general likelihood framework for this type
of analysis. Marginal treatment or exposure effects are modeled with a proportional
hazards model, while correlated transformed survival times are described by a shared
frailty model.
In future work, we hope to extend the transformation in Equation (3) to normal
distributions with variances that can depend on covariates. This type of model can
allow for more explicit analyses into what is driving differences between clusters.
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Table 1: Summary of Simulation Results
Number of clusters = 30

σ
β1
β2

Truth
0.5
-0.693
0.75

Median cluster size =
Estimate
SEJ
SES
0.531
0.117
–
-0.718
0.244
0.217
0.824
0.400
0.366

Frailties

R. Bias
-0.099

SEL
0.911

3
SEM C
0.107
0.236
0.403

Median cluster
Estimate
SEJ
0.559
0.070
-0.709
0.112
0.770
0.177

SEM C
0.759

R. Bias
-0.076

size =
SES
–
0.106
0.168

17
SEM C
0.067
0.109
0.179

SEL
0.797

SEM C
0.838

size =
SES
–
0.077
0.120

17
SEM C
0.050
0.079
0.124

SEL
0.773

SEM C
0.886

size =
SES
–
0.063
0.100

17
SEM C
0.042
0.065
0.104

SEL
0.767

SEM C
0.906

Number of clusters = 60

σ
β1
β2

Truth
0.5
-0.693
0.75

Median cluster size =
Estimate
SEJ
SES
0.520
0.081
–
-0.710
0.163
0.157
0.749
0.275
0.260

Frailties

R. Bias
-0.040

SEL
0.900

3
SEM C
0.076
0.157
0.282

Median cluster
Estimate
SEJ
0.535
0.051
-0.704
0.079
0.762
0.125

SEM C
0.798

R. Bias
-0.067

Number of clusters = 90

σ
β1
β2

Truth
0.5
-0.693
0.75

Median cluster size =
Estimate
SEJ
SES
0.512
0.066
–
-0.704
0.133
0.128
0.773
0.221
0.212

3
SEM C
0.063
0.131
0.229

Median cluster
Estimate
SEJ
0.528
0.042
-0.700
0.064
0.748
0.102

R. Bias
SEL
SEM C
R. Bias
Frailties
-0.032
0.896
0.811
-0.055
Estimate = average of estimates
SEJ = average of jackknifed based standard errors
SES = average of sandwich-formula based standard errors (only for β)
SEL = average of likelihood based standard errors
SEM C = standard deviation of estimates
R. Bias = median relative bias, where relative bias = bias/parameter estimate

Table 2: Treatment arms
Arm
A
B
C
D

for subjects of CCG-1961 with enlarged livers
Strength Duration N
Standard Standard 119
Standard Double 104
Increased Standard 117
Increased Double 120
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Table 3: Data Analysis Results
Parameter

Estimate

SEJ

SES

Naı̈ve SE

Treatment Only Model
Covariates
Increased Strength
Increased Duration

-0.430
0.419

0.231 0.225
0.231 0.226

Frailty Variance
σ

0.171

0.152

–

0.247
0.245

–

Larger Model
Covariates
Increased Strength
Increased Duration
Gender (ref=males)
Age
1–9
10–15
16+
Platelets (×103 /mm3 )
1–49
50–150
150+

-0.418
0.426
-0.101

0.236 0.229
0.247 0.236
0.254 0.243

0.247
0.248
0.251

(ref)
0.415
0.394

0.253 0.244
0.491 0.430

0.262
0.384

(ref)
0.386
-0.118

0.303 0.288
0.643 0.568

0.258
0.529

Frailty Variance
σ
0.175
0.144
–
–
Estimate = log hazard ratios and estimates of σ
SEJ = average of jackknife based standard errors
SES = average of sandwich-formula based standard errors (only for β)
Naı̈ve SE = SE assuming independence
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Appendix A.

Regularity Conditions and Notation

Assume the following regularity conditions where τ > 0 is a constant (for example,
study duration):
C.1: β is in a compact subset of Rp
C.2: Λ(τ ) < ∞
C.3: σ ∈ ν, where ν is a compact subset of (0, 1)
C.4: P (Cij ≥ t ∀t ∈ [0, τ ] | Zij ) > δc > 0 for j = 1, . . . , ni and i = 1, . . . , m
C.5: Write Zij (t) = {Zij1 (t), . . . , Zijp (t)}. |Zijk (0)| +

Rτ
0

|dZijk (t)| ≤ BZ < ∞ almost

surely for some constant BZ and i = 1, . . . , m, j = 1, . . . , ni , k = 1, . . . , p
C.6: E log{L(σ1 ; β, Λ)/L(σ2 ; β, Λ)} exists for all σ1 , σ2 ∈ (0, 1)
C.7: Let Yij (t) = I(Xij ≥ t), K = maxi ni , a⊗0 = 1, a⊗1 = a, a⊗2 = a0 a,
(κ)

Qj (β, t) = m−1

Pm

(κ)

i=1

(1)

ηj (β, t) =

Assume

PK R τ
j=1

0

qj (β ,t)
(0)

qj (β ,t)

(κ)

Yij (t) exp{β 0 Zij (t)}Zij (t)⊗κ , qj (β, t) = EQj (β, t),
(2)

, %j (β, t) =

qj (β ,t)
(0)

qj (β ,t)

− ηk (β, t)⊗2 for j = 1, . . . , K.

(0)

%j (β 0 , t)qj (β 0 , t)λ0 (t) dt is positive definite

Condition C.3 allows us to avoid boundary issues. Condition C.5 assumes that all
the covariates are of bounded variation, which is necessary to ensure the Hadamard
differentiability of the likelihood and score function. Condition C.6 is useful to help
prove that the expected likelihood is maximized at σ0 . Condition C.7 is a technical
condition from Spiekerman and Lin (1998) that is needed for the results for β̂ and Λ̂.
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To simplify the presentation of the proofs we define several terms. Define

∗

L (σ, β, Λ) =

m
Y

∆i
ni −∆i
i
i
φ∆
(X̃ini −∆i | X̃∆
u (X̃i )Φ̃c
i ),

i=1

where L∗ (σ, β, Λ) = c∗ L(σ, β, Λ) and c∗ does not depend on σ. Let

lm0 (σ) = m−1 log L∗ (σ, β 0 , Λ0 ), lm (σ) = m−1 log L∗ (σ, β, Λ),
ˆlm (σ) = m−1 log L∗ (σ, β̂, Λ̂), Um0 (σ) = ∂lm0 (σ)/∂σ, Um0 (σ) = ∂lm (σ)/∂σ,
and Ûm (σ) = ∂ ˆlm (σ)/∂σ

Expectations are with respect to the true distributions of all random variables involved. Let k · k denote the Euclidean norm and let k · k∞ denote the supremum norm
on [0, τ ]. Let BV [0, τ ] denote the class of functions with bounded total variation on
[0, τ ]. Let single superscript dots denote first derivatives and double superscript dots
denote second derivatives.

Appendix B.

Proof and Associated Lemmas for Theorem 1

For ease of presentation we state several lemmas used in the proof of Theorem 1, but
defer their proof until the end of the Appendix.
To account for the fact that plug-in estimates of β and Λ are used in the likelihood
for σ, we will need to take a Taylor series expansion of the likelihood of σ around
β 0 and Λ0 . Since Λ0 is an unspecified function, this expansion will need to include a
functional expansion term. An expansion using Hadamard derivatives is appropriate
for this situation. Hence, in order to use the functional expansion, we need to verify
that the log-likelihood is Hadamard differentiable with respect to Λ, which is done in
Lemma 1.
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Lemma 1. Under conditions C.1–C.5, the log-likelihood lm (σ) is Hadamard differentiable with respect to Λ.
After we have an expansion of the log-likelihood we will need the first order terms
to be bounded by a random variable with finite expectation. We provide this verification in Lemma 2.
Lemma 2. Write the Hadamard derivative of lm (σ) with respect to Λ at Π ∈ BV [0, τ ]
Rτ
as 0 ζm (Λ, σ)(u) dΠ(u) and let ζ m (β, σ) = ∂lm (σ)/∂β. Under conditions C.1–C.5,
kζm (Λ, σ)k∞ and kζ m (β, σ)k are bounded. Expressions for ζ m (β, σ) and ζm (Λ, σ) are
provided in the proof.
In order to prove consistency of σ̂ we will need to verify the uniform convergence
of the log-likelihood with plug-in estimates of β and Λ to the expected value of the
log-likelihood evaluated at the truth. We accomplish this, using the results of Lemmas
1 and 2, in Lemma 3.
Lemma 3. Under conditions C.1–C.5, as m → ∞

sup |ˆlm (σ) − Elm0 (σ)| = op (1).
σ∈ν

Finally, in order to verify that σ̂ is consistent, we will need to show that the
expected log-likelihood is maximized at the truth, which is done in Lemma 4.
Lemma 4. Under conditions C.1–C.6,

Elm0 (σ) − Elm0 (σ0 ) < 0.
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Proof of Theorem 1
The results for β̂ and Λ̂ follow from arguments along the lines of Spiekerman and Lin
(1998). We use the results of Lemmas 3 and 4 to prove the result for σ̂.
Since σ̂ maximizes ˆlm (σ), Lemma 3 implies that
0 ≤ ˆlm (σ̂) − ˆlm (σ0 ) = ˆlm (σ̂) − ˆlm (σ0 ) + Elm0 (σ0 ) − Elm0 (σ0 )
= ˆlm (σ̂) − Elm0 (σ0 ) + op (1).
Therefore Elm0 (σ0 ) ≤ ˆlm (σ̂)+op (1). Subtract Elm0 (σ̂) from each side of the inequality
to write

Elm0 (σ0 ) − Elm0 (σ̂) ≤ ˆlm (σ̂) − Elm0 (σ̂) + op (1)
≤ sup |ˆlm (σ) − Elm0 (σ)| + op (1) = op (1),

(8)

σ∈ν

where the last equality comes from Lemma 3.
Take σ such that |σ − σ0 | ≥ ε for any fixed ε > 0. By Lemma 4 there must exist
some γε > 0 such that Elm0 (σ) + γε < Elm0 (σ0 ). It follows that P (|σ̂ − σ0 | ≥ ε) ≤
P {Elm0 (σ̂) + γε < Elm0 (σ0 )}. Equation (8) implies that P {Elm0 (σ̂) + γε < Elm0 (σ0 )}
converges to 0 as m → ∞. Therefore P (|σ̂ − σ0 | ≥ ε) converges to 0 as m → ∞.

Appendix C.

Proof and Associated Lemmas for Theorem 2

For ease of presentation we state several lemmas used in the proof of Theorem 2, but
defer their proof until the end of the Appendix.
To account for the fact that plug-in estimates of β and Λ are used in the likelihood
and score function for σ, we will need to take a Taylor series expansion of the score
function for σ around β 0 and Λ0 . We verify that the score function is Hadamard
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differentiable with respect to Λ, which is done in Lemma 5.
Lemma 5. Under conditions C.1–C.5, the score function Um (σ) is Hadamard differentiable with respect to Λ.
After we have an expansion of the score function for σ, we will need the first order
terms to be bounded by a random variable with finite expectation. We provide this
verification in Lemma 6.
Lemma 6. Write the Hadamard derivative of Um (σ) with respect to Λ at Π ∈ BV [0, τ ]
Rτ
as 0 ξm (σ, Λ)(u) dΠ(u) and let ξ m (β, σ) = ∂Um (σ)/∂β. Under conditions C.1–C.5,
kξm (σ, Λ)k∞ and kξ m (σ, β)k are bounded. Expressions for ξ m (σ, β) and ξm (σ, Λ) are
provided in the proof.
Proof of Theorem 2
√
The result that m(β̂ − β) converges to mean zero normal distribution and that
√
m(Λ̂ − Λ0 ) converges to mean zero Guassian process follows from arguments along
√
the lines of Spiekerman and Lin (1998). This proof needs to verify that m(σ̂ − σ0 )
converges to a normal distribution with mean zero after accounting for the extra
variance induced by the profile estimation procedure. The variance of σ̂ should be
inflated over a model where β 0 and Λ0 are used to take into account the estimation
of β̂ and Λ̂.
First we will show that the score equation associated with ˆlm evaluated at σ0
follows a normal distribution. This result coupled with a first order expansion of the
score equation associated with ˆlm around σ0 will finish the proof.
Using Lemma 5, a Taylor series expansion of Ûm (σ) around β 0 and Λ0 gives
Z

τ

ξm (σ0 , Λ)(t) d{Λ̂(t) − Λ0 (t)} + ξ m (σ0 , β)(β̂ − β) + Gm ,

Ûm (σ0 ) = Um (σ0 ) +
0
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where Gm is a remainder term for the Taylor series. Since Λ̂ and β̂ are

√

m-consistent

it can be shown that Gm = op (m−1/2 ). Define the pointwise limit of ξm (σ, Λ)(t) as
ξ(σ, Λ)(t) and let ξ(σ, β) = Eξ m (σ, β). From Lemma 6, kξ(σ0 , Λ)k∞ and kξ(σ, β)k
are bounded. It follows that
√

Z τ
√
√
ξ(σ0 , Λ)(t) d{Λ̂(t) − Λ0 (t)}
mÛm (σ0 ) = mUm (σ0 ) + m
0
√
+ m ξ(σ0 , β)(β̂ − β) + op (1).

(9)

Using the results of Spiekerman and Lin (1998), we can write Equation (9) as a
√ P
sum of independent and identically distributed random variables, m m
i=1 Ξi , where
√
EΞ1 = 0 and V Ξ1 < ∞. The central limit theorem implies that mÛm (σ0 ) converges
to a normally distributed random variable with mean zero and variance equal to the
variance of Ξ1 .
Next, we take a first order Taylor series expansion of Ûm (σ̂) around σ0 :
Ûm (σ̂) = Ûm (σ0 ) + (σ̂ − σ0 )Ŵm (σ ∗ ),

where Ŵm (σ) = ∂ Ûm (σ)/∂σ and σ ∗ is between σ̂ and σ0 . It must be the case that
Ûm (σ̂) = 0 since σ̂ was taken to be the maximum of L(σ, β̂, Λ̂). Theorem 1 showed
that σ̂ consistently estimates σ0 , so the the law of large numbers implies that Ŵm (σ ∗ )
converges in probability to W (σ0 ) = limm→∞ Wm (σ0 ). Finally, using the central limit
√
theorem and Slutsky’s theorem, m(σ̂ − σ0 ) converges to a normal distribution with
mean zero and variance equal to W (σ0 )−2 V (Ξ1 ).
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Appendix D.

Proofs of Lemmas

Proof of Lemma 1
Define Yij (t) = I(Xij ≥ t). The log-likelihood can be written
−1

lm (σ) = m

m
X

∆i
ni −∆i
i
i
log φ∆
(X̃ini −∆i | X̃∆
u (X̃i ) + log Φ̃c
i )

i=1

where X̃ij = Φ̃−1 (exp[−

Rτ
0

Yij (u) exp{β 0 Zij (u)} dΛ(u)]). By condition C.5 the term
Z

τ

Yij (u) exp{β 0 Zij (u)} dΛ(u)

0

is Hadamard differentiable. Using multiple iterations of the chain rule for Hadamard
derivatives (van der Vaart 1998, Theorem 20.9), we conclude that lm (σ) is Hadamard
differentiable.
Proof of Lemma 2
First we find expressions for ζm (σ, Λ) and ζ m (β, σ), starting with ζm (σ, Λ). To make
the argument more concrete express lm (σ) as a function of Λ by writing lm (σ, Λ) =
lm (σ). Let Γ ∈ BV [0, τ ]. Denote
Z
Hij = exp[−

τ

Yij (u) exp{β 0 Zij (u)} dΛ(u)].

0

By conditions C.1 and C.2, for j = 1, . . . , ni and i = 1, . . . , m, Hij > 0 and |X̃ij | <
B ∗ < ∞ for some constant B ∗ .
To find the expression for the derivative, take a Taylor series expansion of lm {σ, Λ+
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t(Γ − Λ)} around t = 0 and evaluate the result at t = 1. The final expression is
Z

τ

ζm (σ, Λ)(u) d(Λ − Γ)(u),

lm (σ, Γ) = lm (σ, Λ) +
0

where ζm (σ, Λ)(u) is equal to m−1

Pm Pni
i=1

j=1

l
l
Dij
Yij (u) exp{β 0 Zij (u)}Hij and Dij
is

equal to
−1

−1

∆i
∆i
∆i
ni −∆i
i
i
(∆ij [φ∆
(X̃ini −∆i | X̃∆
u (X̃i ) {∂φu (X̃i )/∂ X̃ij }] + (1 − ∆ij )[Φ̃c
i )
ni
X
ni −∆i
∆i
ni −∆i
×{∂ Φ̃c
(X̃i
| X̃i )/∂ X̃ij }])
∂Φ−1 (Hij )/∂Hij .
j=1

Therefore the Hadamard derivative for Π ∈ BV [0, τ ] is

Rτ
0

ζm (σ, Λ)(u) dΠ(u). Direct

calculation verifies that ζ m (σ, β) is equal to
−1

m

ni
m X
X
i=1 j=1

l
Dij
[

Z

τ

Yij (u)Zij (u) exp{β 0 Zij (u)} dΛ(u)]Hij .

0

l
is bounded and also that the
We need to check whether each of the terms in Dij

terms unique to ζ m (σ, β) and ζm (σ, Λ) are bounded. First,
∆0

∆i
∆i
−∆i /2
i
det(Σi11 )−1/2 exp(−X̃i i Σ−1
φ∆
u (X̃i ) = (2π)
i11 X̃i /2) > 1/B1 > 0

∗
i
for some constant B1 since for X̃ij ∈ X̃∆
i , |X̃ij | < B . Therefore, for i = 1, . . . , m,
∆i −1
i
φ∆
< B1 < ∞.
u (X̃i )

Let wα (j) denote the vector of length α where the j th element is 1 and the rest
of the vector is 0. Using the chain rule, for j = 1, . . . , ∆i and i = 1, . . . , m,
∆0

∆i
∆i
−1
∆i
i
i
∂φ∆
u (X̃i )/∂ X̃ij = −X̃i Σi11 w∆i (j)φu (X̃i ).
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∆i
∆i
∗
i
The multivariate normal density φ∆
u (X̃i ) is bounded and for X̃ij ∈ X̃i , |X̃ij | < B .
∆i
i
Hence, for j = 1, . . . , ∆i and i = 1, . . . , m, |∂φ∆
u (X̃i )/∂ X̃ij | < B2 < ∞ for some

constant B2 .
i
Next consider Φ̃nc i −∆i (X̃ni i −∆i | X̃∆
i ), which for i = 1, . . . , m is equal to

Z

−1

(2π)ni −∆i det(Σ̃i ) exp{(tni −∆i − µ̃i )0 Σ̃i (tni −∆i − µ̃i )/2} dtni −∆i

Mi

where Mi = {t(∆i +1) > X̃i,(∆i +1) , . . . , tni > X̃i,ni }, tni −∆i = (t(∆i +1) , . . . , tni ), Σ̃i =
ni −∆i
−1 ∆i
∗
Σi22 − Σ0i21 Σ−1
, it
i11 Σi12 , and µ̃i = Σi21 Σi11 X̃i . Since |X̃ij | < B for X̃ij ∈ X̃i
i −1
must be the case that for i = 1, . . . , m. |Φ̃cni −∆i (X̃ini −∆i | X̃∆
i ) | < B3 < ∞ for some

constant B3 .
Let tnj i −∆i be equal to tni −∆i but with the component corresponding to (j − ∆i )th
component replaced by X̃ij . Let tn−ji −∆i be equal to tni −∆i but with the (j − ∆i )th
element removed. Let Mi,−j denote Mi but with the (j − ∆th
i ) inequality removed.
i
Consider |∂ Φ̃nc i −∆i (X̃ni i −∆i | X̃∆
i )/∂ X̃ij |, which, for j = ∆i + 1, . . . , ni , i = 1 . . . , m,

can be written
Z
|

−1

−(2π)ni −∆i det(Σ̃i ) exp{(tnj i −∆i − µ̃i )0 Σ̃i (tjni −∆i − µ̃i )/2} dtn−ji −∆i | < B4

Mi

for some constant B4 < ∞ since |X̃ij | < B ∗ for X̃ij ∈ X̃ini −∆i .
Using the definition of the derivative of an inverse function, ∂Φ−1 (Hij )/∂Hij =
−[φ{Φ−1 (Hij )}]−1 , where φ is the density of the standard normal distribution and
Φ−1 is the inverse of the distribution function of the standard normal distribution.
Since |X̃ij | < B ∗ , 0 < B5 < Hij < B6 < 1 for some constants B5 and B6 . Therefore,
for j = 1, . . . , ni and i = 1, . . . , m, |∂Φ−1 (Hij )/∂Hij | < B7 < ∞ for some constant
B7 . By condition C.5, for j = 1, . . . , ni and i = 1, . . . , m, kYij exp(β 0 Zij )k∞ < B8 <
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∞ and k

Rτ
0

Yij (u)Zij (u) exp{β 0 Zij (u)} dΛ(u)]k < B9 < ∞ for some constants B8

and B9 . Hence kζm (σ, Λ)k∞ and kζ m (β, σ)k are bounded are bounded by (B1 B2 +
B3 B4 )B7 (B8 + B9 ) < ∞.
Proof of Lemma 3
An expansion of ˆlm (σ) around Λ0 and β 0 can be written:
ˆlm (σ) = lm0 (σ) + ζ m (β, σ)(β̂ − β) +

Z

τ

ζm (σ, Λ)(t) d(Λ̂ − Λ0 )(t) + R,
0

where R is a remainder term of order op {max(kΛ̂ − Λ0 k∞ , kβ̂ − β 0 k)} and ζ m (β, σ)
and ζm (σ, Λ)(t) are defined in Lemma 2. Since Λ̂ is uniformly consistent and β̂ is
consistent (Spiekerman and Lin 1998), R = op (1). The result follows from the law of
large numbers, the uniform consistency of Λ̂, the consistency of β̂, and the fact that
kζ m (β, σ)k and kζm (σ, Λ)k∞ are bounded (Lemma 2).
Proof of Lemma 4
The log-likelihood, lm (σ), can be written as a sum of independent and identically
P
distributed random variables m−1 m
i=1 ϕi (σ). Take σ 6= σ0 . The law of large numbers
and Jensen’s inequality imply that Elm0 (σ) − Elm0 (σ0 ) = limm→∞ lm0 (σ) − lm0 (σ0 )
which is strictly less than log[E(L∗ (σ, β 0 , Λ0 )/L∗ (σ0 , β 0 , Λ0 ))] = 0.
Proof of Lemma 5
Let N (t, d, µ, Σ† ) be defined as (2π)−d/2 det(Σ† )−1/2 exp{−(t − µ)0 (Σ† )−1 (t − µ)/2}
[tr{(Σ† )−1 W̃d } − {−(t − µ)0 (Σ† )−1 W̃d (Σ† )−1 (t − µ)/2}]/2, where W̃d is the d dimensional square matrix with zeros along the diagonal and ones off the diagonal. Let
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0d denote a vector of length d of zeros. The score function can be written

Um (σ) = m

−1

m
X

∆i −1
∆i
∆i
i
φ∆
u (X̃i ) N (X̃i , ∆i , 0 , Σi11 )

i=1

+Φ̃nc i −∆i (X̃ni i −∆i

|

i −1
X̃∆
i )

Z

N (tni −∆i , ni − ∆i , µ̃i , Σ̃i ) dtni −∆i .

Mi

Using the results of Lemma 1 and multiple iterations of the chain rule for Hadamard
derivatives (van der Vaart 1998, Theorem 20.9), we conclude that Um (σ) is Hadamard
differentiable.
Proof of Lemma 6
First we find expressions for ξm (σ, Λ) and ξ m (σ, β), starting with ξm (σ, Λ). To make
the argument more concrete express Um (σ) as a function of Λ by writing Um (σ, Λ) =
Um (σ). Let Γ ∈ BV [0, τ ].
To find the expression for the derivative, take a Taylor series expansion of Um {σ, Λ+
t(Γ − Λ)} around t = 0 and evaluate the result at t = 1. The final expression
Rτ
is Um (σ, Γ) = Um (σ, Λ) + 0 ξm (σ, Λ)(u) d(Λ − Γ)(u), where ξm (σ, Λ)(u) is equal to
P Pni
0
U
m−1 m
j=1 Dij Yij (u) exp{β Zij (u)}Hij and
i=1
−1

−1

∆i
∆i
∆i
U
∆i
∆i
i
Dij
= (∆ij [{∂φ∆
u (X̃i ) /∂ X̃ij }N (X̃i , ∆i , 0 , Σi11 ) + φu (X̃i )

−1

∆i
ni −∆i
i
i
(X̃ini −∆i | X̃∆
×{∂N (X̃∆
i ) /∂ X̃ij }
i , ∆i , 0 , Σi11 )/∂ X̃ij }] + (1 − ∆ij )[{∂ Φ̃c
Z
−1
i
×
N (tni −∆i , ni − ∆i , µ̃i , Σ̃i ) dtni −∆i + Φ̃nc i −∆i (X̃ini −∆i | X̃∆
i )
Mi

Z
×{∂

N (t

ni −∆i

ni −∆i

, ni − ∆i , µ̃i , Σ̃i ) dt

/∂ X̃ij }])

Mi

Therefore the Hadamard derivative for Π ∈ BV [0, τ ] is

ni
X

∂Φ−1 (Hij )/∂Hij

j=1

Rτ
0

ξm (σ, Λ)(u) dΠ(u). Direct

Hosted by The Berkeley Electronic Press

calculation verifies that ξ m (σ, β) is equal to
−1

m

ni
m X
X

U
Dij
[

i=1 j=1

Z

τ

Yij (u)Zij (u) exp{β 0 Zij (u)} dΛ(u)]Hij .

0

∆i −1
i
In Lemma 2 we showed that, for i = 1, . . . , m, |φ∆
u (X̃i ) | < B1 < ∞ and

|Φ̃nc i −∆i (X̃ni i −∆i )−1 | < B3 < ∞. Also, for j = 1, . . . , ni , i = 1, . . . , m, |∂Φ−1 (Hij )/∂Hij | <
Rτ
B7 < ∞, kYij exp(β 0 Zij )k∞ < B8 < ∞ and k 0 Yij (u)Zij (u) exp{β 0 Zij (u)} dΛ(u)]k <
B9 < ∞.
We tackle each of the remaining terms. First, using results from Lemma 2, for j =
−1

∆i
∆i −2
∆i
∆i
∆i
i
1, . . . , ∆i , i = 1, . . . , m, |∂φ∆
u (X̃i ) /∂ X̃ij | is equal to |−φu (X̃i ) {∂φu (X̃i )/∂ X̃ij }| <

B11 = B12 B2 < ∞ for some constant B11 .
−1/2
Since Σi11 has an exchangeable structure, tr{Σ−1
are both
i11 W̃∆i } and det(Σi11 )
∆i
i
bounded by some constant B10 < ∞. Therefore for i = 1, . . . , m, |N (X̃∆
i , ∆i , 0 , Σi11 )| <

B12 < ∞ for some constant B12 .
∆i
i
Next, we consider |∂N (X̃∆
i , ∆i , 0 , Σi11 )/∂ X̃ij | for j = 1, . . . , ∆i and i = 1, . . . , m,

which is equal to
∆0

∆0

∆i
∆i
−1
−1
∆i
∆i
i
|X̃i i Σ−1
i11 w∆i (j)N (X̃i , ∆i , 0 , Σi11 ) + X̃i Σi11 W̃∆i Σi11 w∆i (j)φu (X̃i )|,

and, by the results of the previous paragraph and the results of Lemma 2, is bounded
by some constant B13 < ∞.
Using results from Lemma 2, for j = ∆i + 1, . . . , ni and i = 1, . . . , m,
−1

i
|∂Φnc i −∆i (X̃ni i −∆i | X̃∆
i ) /∂ X̃ij | is equal to

ni −∆i
2
i −2
i
| − Φnc i −∆i (X̃ni i −∆i | X̃∆
(X̃ini −∆i | X̃∆
i ) {∂Φc
i )/∂ X̃ij }| < B14 = B3 B4 < ∞
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for some constant B14 .
Using similar arguments as above one can directly show that for i = 1, . . . , m,
R
Mi

N (tni −∆i , ni − ∆i , µ̃i , Σ̃i ) dtni −∆i < B15 < ∞ for some constant B15 .
Also, for j = ∆i + 1, . . . , ni and i = 1, . . . , m,
Z
|∂

N (tni −∆i , ni − ∆i , µ̃i , Σ̃i ) dtni −∆i /∂ X̃ij
Mi
Z
ni −∆i
=
N (tnj i −∆i , ni − ∆i , µ̃i , Σ̃i ) dt−j
| < B15 < ∞
Mi,−j

for some constant B16 .
Hence kξm (σ, Λ)k∞ and kξ m (β, σ)k are bounded are bounded by (B11 B12 +B1 B13 +
B14 B15 + B3 B16 )B7 (B8 + B9 ) < ∞.
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